Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.44
+0.04 (+0.26%)
Streaming Delayed Price
Updated: 2:40 PM EDT, Jul 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
16
17
Next >
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
May 11, 2022
Via
Benzinga
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
May 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
April 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder
January 31, 2022
The
Via
Benzinga
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
April 22, 2022
Via
Benzinga
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay
April 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Novavax Stock Looks Like a Good Value With Its New Combined Vaccine
April 21, 2022
NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials.
Via
InvestorPlace
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
April 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report
April 18, 2022
Via
Benzinga
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States
April 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference
April 13, 2022
Via
Benzinga
Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027
April 13, 2022
Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent...
Via
FinancialNewsMedia
Exposures
COVID-19
Takeda Announces Completion of Acquisition of Own Shares
April 13, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
April 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)
April 12, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners
April 05, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Monday Markets News
March 28, 2022
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved.
Via
Talk Markets
Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
March 28, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
March 08, 2022
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID...
Via
Benzinga
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
February 28, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
February 22, 2022
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly...
Via
Benzinga
Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics
February 22, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four...
Via
Benzinga
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months
February 18, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of...
Via
Benzinga
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2
February 18, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
The Best Russell 2000 Stocks to Buy Before they Rebound
February 15, 2022
Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices.
Via
InvestorPlace
Why Are Seagen Shares Sinking Today?
February 10, 2022
Seagen Inc (NASDAQ: SGEN) reported Q4 revenues
Via
Benzinga
Take a Leap Into Novavax Stock After Vaccine Sales Start
February 08, 2022
Novavax is worth speculating on at current levels. NVAX stock has fallen below the $100 mark ahead of its global Covid-19 vaccine launch.
Via
InvestorPlace
A News Blizzard
February 04, 2022
Markets are still down despite very encouraging news in January when 467,00 new hires got jobs.
Via
Talk Markets
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum
February 03, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
January 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.